What Is Prior Authorization?
Prior authorization requires your provider to demonstrate medical necessity before your insurer covers Mounjaro. For diabetes patients, this means documenting type 2 diabetes that warrants a GLP-1/GIP agonist.
Important distinction: Mounjaro is FDA-approved for type 2 diabetes only, not weight loss. For weight management, the appropriate product is Zepbound with its own PA process. See our Zepbound Insurance Appeal Guide.
Common Insurer Requirements
| Requirement | Details |
|---|---|
| Confirmed T2D diagnosis | ICD-10 code documentation |
| HbA1c level | Typically >7.0% (varies by plan) |
| Step therapy | Trial/failure of metformin or documented intolerance |
| Lifestyle modifications | Diet/exercise documentation |
| Prescriber credentials | NPI and provider information |
The PA Process
- Provider writes Mounjaro prescription
- Pharmacy identifies PA requirement
- Provider submits PA with documentation
- Insurer reviews (48–72 hours standard)
- Decision: approved, denied, or more info needed
- If approved, valid for 6–12 months
Thorough documentation submitted upfront significantly increases approval rates and reduces delays.
Common Denial Reasons
- Step therapy not completed
- Insufficient documentation or missing lab values
- HbA1c below insurer’s threshold
- Insurer prefers a different GLP-1 medication
- Administrative errors
How to Appeal
Internal Appeal
Provider submits formal appeal with additional evidence. Include peer-reviewed data supporting Mounjaro’s clinical advantages. Address the specific denial reason directly.
External Review
Independent physician reviewer evaluates the case. External reviews are binding if approved.
Peer-to-Peer Review
Phone conversation between your provider and the insurer’s medical director—often the most efficient resolution pathway.
How PEAK Handles PA
- Pre-verification: We check your insurance requirements before your first visit
- Full submission: Complete documentation with first request
- Tracking: We monitor status and follow up proactively
- Appeals: We handle the full appeal process including peer-to-peer reviews
- Alternatives: If PA is unsuccessful, we identify alternative coverage pathways
We maintain a strong prior authorization approval rate because we submit thorough documentation and know each major insurer’s requirements.
Boxed warning — thyroid C-cell tumors: Tirzepatide (Mounjaro/Zepbound) carries an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
PEAK accepts commercial insurance and TRICARE. We do not accept Medicare or Medicaid, including Medicare Advantage and Medicaid managed care plans.
